← All organizations
Highest phase reached
Phase 4
First clinical trial
May 1, 2001Last known activity
Oct 12, 2020
Timeline
1990s
- Jun 1, 1998
Sanquin— Founded
Drugs by trial phase (21 distinct, 27 trials)
Phase 4 (10 own, 0 via acquisition)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (4 own, 0 via acquisition)
Indications
Studied for
- Agammaglobulinemia
- Angioedema
- Angioedemas, Hereditary
- Asthma
- beta-Thalassemia
- Cardiomyopathies
- Endotoxemia
- Erythroblastosis, Fetal
- Hemophilia A
- Hemophilia B
- Hereditary Angioedema Types I and II
- Hidradenitis
- Hidradenitis Suppurativa
- Hip Fractures
- HIV Infections
- IgG Deficiency
- Immunologic Deficiency Syndromes
- Infections
- Inflammation
- Metal Metabolism, Inborn Errors
- Multiple Organ Failure
- Multiple Sclerosis
- Neutropenia
- Osteoarthritis
- Parvoviridae Infections
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
- Sclerosis
- Thalassemia
- Wounds and Injuries
Recent trials (30)
- NCT04589949CollaboratorPhase 3Oct 12, 2020
- NCT03993613Lead sponsorPhase 2Mar 21, 2019
- NCT03899142Lead sponsorPhase 1Jan 28, 2019
- NCT03221621CollaboratorPhase 4Aug 1, 2017
- NCT03085290Lead sponsorN/AJun 26, 2017
- NCT03104426Overall official - principal investigatorPhase 2/Phase 3Jun 1, 2017
- NCT03104426Lead sponsorPhase 2/Phase 3Jun 1, 2017
- NCT03051698CollaboratorPhase 4Nov 16, 2016
- NCT03516526CollaboratorPhase 4Nov 3, 2016
- NCT01985373Lead sponsorPhase 3Dec 1, 2013
- NCT01766414CollaboratorPhase 3Sep 1, 2013
- NCT01275976CollaboratorPhase 3Apr 1, 2012
- NCT01797055Lead sponsorPhase 2/Phase 3Dec 1, 2010
- NCT02783313Lead sponsorN/ANov 17, 2010
- NCT00892112Lead sponsorPhase 3Nov 1, 2009
Details
- Founded
- Amsterdam, NL Jun 1, 1998
- Last known activity
- Oct 12, 2020